Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
 Your new post is loading...
Your new post is loading...
Scoop.it!
Nasdaq-traded marijuana stocks are undervalued as investors remain skittish and the use of drugs produced by these biopharmaceutical companies have not been widely adopted. 
No comment yet.
Sign up to comment
Scoop.it!
From
fortune
GW Pharmaceuticals' marijuana-based drug Epidiolex could become the first U.S.-approved prescription drug derived from marijuana.
|
Scoop.it!
Positive late-stage data on Epidiolex drug sets up FDA approval process.Results suggest rich promise for whole range of cannabinoid drugs under testing.Other me
Shinji's insight:
Other Medical Marijuana Companies.
GWPH shares soared 120% overnight on the news of these results. The news also lifted the share price of other companies in the medical marijuana space. The following day some of the huge up-swings in other medical marijuana stocks moderated quite substantially. These include Insys Therapeutics (NASDAQ:INSY) and Zynerba Pharmaceuticals (NASDAQ:ZYNE). I touched on these in my December article and both to my mind come with significant negative riders.
|
